Amendments to the Claims

The following claims will replace all prior versions and listings of claims in the application, and are marked to show changes.

1-6. (Canceled)

7. (Currently amended) A prostatic stent for use in a patient comprising:

(a) a first segment locatable on the proximal side of the patient's external urinary sphincter and including an external surface, an internal surface, a proximal portion, a distal end, a lumen defined by the internal surface and extending within the first segment, ~~a channel disposed between the external surface and the internal surface,~~ and a plurality of openings ~~in communication with the channel~~ for conveying at least one agent from the lumen to the external surface ~~via the channel~~, the proximal portion including at least one opening in communication with the lumen for receiving fluid from the bladder of the patient, the distal end terminating on the proximal side of the external urinary sphincter when the prostatic stent is placed within the body of the patient;

(b) a second segment locatable on the distal side of the external urinary sphincter of the patient and including an external surface, an internal surface, a proximal end, a distal end, and a lumen defined by the internal surface and extending within the second segment, the proximal end terminating on the distal side of the external urinary sphincter when the prostatic stent is placed within the body of the patient; ~~and~~

(c) a connecting segment disposed between the first and second segments and coupling together the first and second segments; and

(d) an anticoagulant disposed on the internal surface of the first segment.

8. (Canceled)

9. (Currently amended) The stent according to claim 7 further comprising an anticoagulant on ~~each of~~ the internal surface ~~surfaces~~ of the ~~first and~~ second segment ~~segments~~.

10. (Previously presented) The stent according to claim 9 wherein the anticoagulant is selected from the group consisting of acenocoumarol, ancrod, anisindione, bromindione, clorindione, coumetarol, cyclocumarol, dextran sulfate sodium, dicumarol, diphenadione, ethyl biscoumacetate, ethylidene dicoumarol, fluindione, heparin, hirudin, lyapolate sodium, oxazidione, pentosan polysulfate, phenindione, phenprocoumon, phosvitin, picotamide, tioclomarol and warfarin.

11. (Original) The stent according to claim 7 further comprising a polymerizable agent on the external surface of the first segment.

12. (Previously presented) The stent according to claim 11 wherein the polymerizable agent is a polymerizable hemostatic agent selected from the group consisting offibrinogen, alginate, and collagen.

13. (Canceled)

14. (Currently amended) The stent according to claim 11 further comprising an anticoagulant on the internal surface ~~surfaces~~ of the ~~first and~~ second segment ~~segments~~.

15. (Previously presented) The stent according to claim 14 wherein the anticoagulant is selected from the group consisting ofacenocoumarol, ancrod, anisindione, bromindione, clorindione, coumetarol, cyclocumarol, dextran sulfate sodium, dicumarol, diphenadione, ethyl biscoumacetate, ethylidene dicoumarol, fluindione, heparin, hirudin, lyapolate sodium, oxazidione, pentosan polysulfate, phenindione, phenprocoumon, phosvitin, picotamide, tioclomarol and warfarin.

16-18. (Canceled)